Ph.D. Candidate

[Published] 

• Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety [Diabetes Metabolism Research and Reviews] 

• Intrahepatic cholestasis of pregnancy associated with azathioprine: first quantitative disproportionality analysis using the FDA adverse event reporting system [JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES]. 

• Identifying signals of disproportionate reporting for calcitonin gene-related peptide inhibitors: real-world evidence from the FDA adverse event reporting system [Expert Opinion on Drug Safety]. 

• Navigating Recent Changes in Dosing Information: Dynamics of FDA-Approved Monoclonal Antibodies in Post-Marketing Realities [Clinical and Translational Science]. 

• Disproportionality analysis of Raynaud’s phenomenon associated with calcitonin gene-related peptide inhibitors using the Food and Drug Administration adverse event reporting system [Scientific Reports]. 

M.S. Candidate

[Published] 

• Toward Genotype-Informed Dosing of Voriconazole: Head-to-Head Simulations Across CYP2C19 Phenotypes Using Population Pharmacokinetic Models [Pharmaceutics] 

Undergraduate 5

[Published]

• Model-informed prediction of human pharmacokinetics and first-in-human dose selection of J2H-1702, a novel 11β-hydroxysteroid dehydrogenase type 1 inhibitor for metabolic-associated steatohepatitis [European Journal of Pharmaceutical Sciences]. 

Undergraduate 4

[Published]

• Intrahepatic cholestasis of pregnancy associated with azathioprine: first quantitative disproportionality analysis using the FDA adverse event reporting system [Journal of Pharmacy & Pharmaceutical Sciences]. 

Undergraduate 4

Undergraduate 3